Weekly epirubicin in patients with hormone-resistant prostate cancer.
about
Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the scienceDocetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis.Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature.Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer.Salvage chemotherapy for hormone-refractory prostate cancer: Association of Adriamycin and ifosfamide.
P2860
Weekly epirubicin in patients with hormone-resistant prostate cancer.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Weekly epirubicin in patients with hormone-resistant prostate cancer.
@ast
Weekly epirubicin in patients with hormone-resistant prostate cancer.
@en
type
label
Weekly epirubicin in patients with hormone-resistant prostate cancer.
@ast
Weekly epirubicin in patients with hormone-resistant prostate cancer.
@en
prefLabel
Weekly epirubicin in patients with hormone-resistant prostate cancer.
@ast
Weekly epirubicin in patients with hormone-resistant prostate cancer.
@en
P2093
P2860
P356
P1476
Weekly epirubicin in patients with hormone-resistant prostate cancer.
@en
P2093
A I Fiaschi
A Manganelli
D Pozzessere
F Salvestrini
G Francini
M Sabatino
R Petrioli
S Messinese
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600525
P407
P577
2002-09-01T00:00:00Z
P5875
P6179
1023388549